SEARCH

SEARCH BY CITATION

References

  • 1
    Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy–definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 71621.
  • 2
    Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007; 25(Suppl. 1): 39.
  • 3
    Khungar V, Poordad F. Hepatic encephalopathy. Clin Liver Dis 2012; 16: 30120.
  • 4
    Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999; 30: 8905.
  • 5
    Crespin J, Nemcek A, Rehkemper G, Blei AT. Intrahepatic portal-hepatic venous anastomosis: a portal-systemic shunt with neurological repercussions. Am J Gastroenterol 2000; 95: 156871.
  • 6
    Bajaj JS. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther 2010; 31: 53747.
  • 7
    Riggio O, Efrati C, Catalano C, et al. High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology 2005; 42: 115865.
  • 8
    Ohnishi K, Sato S, Saito M, et al. Clinical and portal hemodynamic features in cirrhotic patients having a large spontaneous splenorenal and/or gastrorenal shunt. Am J Gastroenterol 1986; 81: 4505.
  • 9
    Cordoba J. New assessment of hepatic encephalopathy. J Hepatol 2011; 54: 103040.
  • 10
    Laleman W, Simon-Talero M, Maleux G, et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology 2013; 57: 244857.
  • 11
    Uflacker R, Silva Ade O, d'Albuquerque LA, Piske RL, Mourao GS. Chronic portosystemic encephalopathy: embolization of portosystemic shunts. Radiology 1987; 165: 7215.
  • 12
    Boixadera H, Tomasello A, Quiroga S, et al. Successful embolization of a spontaneous mesocaval shunt using the Amplatzer Vascular Plug II. Cardiovasc Intervent Radiol 2010; 33: 10448.
  • 13
    Mukund A, Rajesh S, Arora A, et al. Efficacy of balloon-occluded retrograde transvenous obliteration of Large spontaneous lienorenal shunt in patients with severe recurrent hepatic encephalopathy with foam sclerotherapy: initial experience. J Vasc Interv Radiol 2012; 23: 12006.
  • 14
    Gwon DI, Ko GY, Yoon HK, et al. Gastric varices and hepatic encephalopathy: treatment with vascular plug and gelatin sponge-assisted retrograde transvenous obliteration–a primary report. Radiology 2013; 268: 2817.
  • 15
    Kumamoto M, Toyonaga A, Inoue H, et al. Long-term results of balloon-occluded retrograde transvenous obliteration for gastric fundal varices: hepatic deterioration links to portosystemic shunt syndrome. J Gastroenterol Hepatol 2010; 25: 112935.
  • 16
    Blei AT, Cordoba J; Practice Parameters Committee of the American College of G. Hepatic encephalopathy. Am J Gastroenterol 2001; 96: 196876.
  • 17
    Bajaj JS, Cordoba J, Mullen KD, et al. Review article: the design of clinical trials in hepatic encephalopathy–an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 2011; 33: 73947.
  • 18
    Mullen KD. Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy. Aliment Pharmacol Ther 2007; 25(Suppl 1): 116.
  • 19
    Torlot FJ, McPhail MJ, Taylor-Robinson SD. Meta-analysis: the diagnostic accuracy of critical flicker frequency in minimal hepatic encephalopathy. Aliment Pharmacol Ther 2013; 37: 52736.
  • 20
    Salam M, Matherly S, Farooq IS, et al. Modified-orientation log to assess hepatic encephalopathy. Aliment Pharmacol Ther 2012; 35: 91320.
  • 21
    Sanyal A, Younossi ZM, Bass NM, et al. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther 2011; 34: 85361.
  • 22
    Bajaj JS, Sanyal AJ, Bell D, Gilles H, Heuman DM. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. Aliment Pharmacol Ther 2010; 31: 10127.
  • 23
    Kim KW, Lee J, Lee H, et al. Right lobe estimated blood-free weight for living donor liver transplantation: accuracy of automated blood-free CT volumetry–preliminary results. Radiology 2010; 256: 43340.
  • 24
    Sakurabayashi S, Sezai S, Yamamoto Y, Hirano M, Oka H. Embolization of portal-systemic shunts in cirrhotic patients with chronic recurrent hepatic encephalopathy. Cardiovasc Intervent Radiol 1997; 20: 1204.
  • 25
    Watanabe K, Kimura K, Matsutani S, Ohto M, Okuda K. Portal hemodynamics in patients with gastric varices. A study in 230 patients with esophageal and/or gastric varices using portal vein catheterization. Gastroenterology 1988; 95: 43440.
  • 26
    Jiao LR, Seifalian AM, Mathie RT, Habib N, Davidson BR. Portal flow augmentation for liver cirrhosis. Br J Surg 2000; 87: 98491.
  • 27
    Zidi SH, Zanditenas D, Gelu-Simeon M, et al. Treatment of chronic portosystemic encephalopathy in cirrhotic patients by embolization of portosystemic shunts. Liver Int 2007; 27: 138993.
  • 28
    Leithead JA, Hayes PC, Ferguson JW. Review article: advances in the management of patients with cirrhosis and portal hypertension-related renal dysfunction. Aliment Pharmacol Ther 2014; 39: 699711.
  • 29
    Cardoso JE, Giroux L, Kassissia I, et al. Liver function improvement following increased portal blood flow in cirrhotic rats. Gastroenterology 1994; 107: 4607.
  • 30
    Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 244255.
  • 31
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 32
    Rutter K, Hofer H, Beinhardt S, et al. Durability of SVR in chronic hepatitis C patients treated with peginterferon-alpha2a/ribavirin in combination with a direct-acting anti-viral. Aliment Pharmacol Ther 2013; 38: 11823.
  • 33
    Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 46875.
  • 34
    Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 88693.
  • 35
    D'Ambrosio R, Aghemo A, Rumi MG, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012; 56: 53243.
  • 36
    Herrero JI, Bilbao JI, Diaz ML, et al. Hepatic encephalopathy after liver transplantation in a patient with a normally functioning graft: treatment with embolization of portosystemic collaterals. Liver Transpl 2009; 15: 1114.